Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTUNASDAQ:CEMINASDAQ:NRBONASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.98+1.0%$1.31$0.95▼$3.23$12.09M-0.1321,229 shs181,544 shsCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsNRBONeuroBo Pharmaceuticals$0.79-2.5%$1.05$2.08▼$5.30$6.81M-0.2647,183 shs336,069 shsQLGNQualigen Therapeutics$3.65-3.2%$3.50$2.85▼$29.44$2.69M-0.07112,840 shs5,494 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma+1.02%-2.46%+80.82%+55.29%-38.13%CEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%NRBONeuroBo Pharmaceuticals0.00%+12.99%-3.99%-49.82%-80.88%QLGNQualigen Therapeutics-3.18%-2.41%+5.19%+12.62%-76.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma1.9542 of 5 stars0.03.00.03.44.41.70.6CEMIChembio DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 0.00N/AN/AN/ACEMIChembio Diagnostics 0.00N/AN/AN/ANRBONeuroBo Pharmaceuticals 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81.66M0.15N/AN/A$4.64 per share0.43CEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/AQLGNQualigen Therapeutics$4.98M0.54N/AN/A($20.31) per share-0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A-7.62%-19.30%-4.80%N/ACEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)QLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%5/29/2025 (Estimated)Latest NRBO, QLGN, CEMI, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ACEMIChembio DiagnosticsN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.320.980.81CEMIChembio DiagnosticsN/A1.231.04NRBONeuroBo PharmaceuticalsN/A2.412.41QLGNQualigen TherapeuticsN/A0.520.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%CEMIChembio Diagnostics8.65%NRBONeuroBo Pharmaceuticals1.37%QLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%CEMIChembio Diagnostics3.30%NRBONeuroBo Pharmaceuticals1.05%QLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableQLGNQualigen Therapeutics50736,000723,000Not OptionableNRBO, QLGN, CEMI, and AYTU HeadlinesRecent News About These CompaniesQualigen Therapeutics faces potential Nasdaq delistingMay 21, 2025 | uk.investing.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics Faces Nasdaq Delisting NotificationMay 19, 2025 | tipranks.comQualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing DeficiencyMay 19, 2025 | quiverquant.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QMay 19, 2025 | globenewswire.comMarizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo FinanceMay 10, 2025 | finance.yahoo.comQualigen Therapeutics Faces Nasdaq Delisting ThreatMay 1, 2025 | tipranks.comQualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-KMay 1, 2025 | globenewswire.comQualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire MarizymeApril 1, 2025 | finance.yahoo.comQualigen Therapeutics Delays Yearly Financial ReportApril 1, 2025 | tipranks.comQualigen Therapeutics to participate in next funding round for NanoSynexJanuary 28, 2025 | markets.businessinsider.comQualigen to invest in NanoSynex, stock tumbles 21%January 28, 2025 | msn.comQualigen to participate in next funding round for NanoSynexJanuary 28, 2025 | markets.businessinsider.comQualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity RequirementDecember 6, 2024 | markets.businessinsider.comQualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price and Equity RequirementsDecember 5, 2024 | quiverquant.comUnivest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)November 25, 2024 | globenewswire.comQualigen Therapeutics secures $4.5 million in fundingNovember 21, 2024 | investing.comQualigen announces $4.5M private placement of Preferred SharesNovember 20, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRBO, QLGN, CEMI, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$1.98 +0.02 (+1.02%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.99 +0.01 (+0.51%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Chembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.79 -0.02 (-2.48%) As of 05/23/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Qualigen Therapeutics NASDAQ:QLGN$3.65 -0.12 (-3.18%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$3.49 -0.16 (-4.41%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Advance Auto Parts: Did Earnings Defuse Tariff Concerns? Apple Sinks After New 25% Tariff Announcement—What's The Bottom? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
